Drug Database · Clinicians

Cilostazol

Brands (47) Clauden, Cilostadin, Cilostan Cr…Show all

Phosphodiesterase 3 Inhibitor (Phosphodiesterase 3 Inhibitors) US FDA class
Antithrombotic agent (platelet aggregation inhibitor); Platelet aggregation inhibitor; and others PH FDA category

Rx · Prescription drug85 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 7c841eed-a98f-43c3-baaf-bf5502207a69, version date October 1, 2026 (CILOSTAZOL · Aurobindo Pharma Limited). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. Cilostazol tablets are a phosphodiesterase III inhibitor (PDE III inhibitor) indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance (1)

Contraindications

4 CONTRAINDICATIONS Cilostazol tablets are contraindicated in patients with: Heart failure of any severity: Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV heart failure. Hypersensitivity to cilostazol or any components of cilostazol tablets (e.g., anaphylaxis, angioedema) Heart failure of any severity (4) Hypersensitivity to cilostazol or any components of cilostazol tablets (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • The recommended dosage of cilostazol tablets is 100 mg twice daily taken at least half an hour before or two hours after breakfast and dinner (2.1)
  • Reduce the dose to 50 mg twice daily when coadministered with CYP3A4 inhibitors such as ketoconazole, itraconazole, erythromycin, and diltiazem, or CYP2C19 inhibitors such as ticlopidine, fluconazole, and omeprazole (2.2)
2.1 Recommended

2.1 Recommended dosage The recommended dosage of cilostazol tablets is 100 mg twice daily taken at least half an hour before or two hours after breakfast and dinner. Patients may respond as early as 2 to 4 weeks after the initiation of therapy, but treatment for up to 12 weeks may be needed before a beneficial effect is experienced.

If symptoms are unimproved after 3 months, discontinue cilostazol tablets.

2.2 Dose Reduction with CYP3A4 and CYP2C19 Inhibitors

2.2 Dose Reduction with CYP3A4 and CYP2C19 Inhibitors Reduce dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, erythromycin, and diltiazem) or inhibitors of CYP2C19 (e.g., ticlopidine, fluconazole, and omeprazole) [see Drug Interactions (7.1)].

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations, pharmacokinetics)

8.7 Renal Impairment No dose adjustment is required in patients with renal impairment. Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95 to 98%) [see Clinical Pharmacology (12.3)].

Renal Impairment: The total pharmacologic activity of cilostazol and its metabolites was similar in subjects with mild to moderate renal impairment and in healthy subjects. Severe renal impairment increases metabolite levels and alters protein binding of the parent. The expected pharmacologic activity, however, based on plasma concentrations and relative PDE III inhibiting potency of parent drug and metabolites, appeared little changed.

Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95 to 98%).

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.6 Hepatic Impairment No dose adjustment is required in patients with mild hepatic impairment. Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided [see Clinical Pharmacology (12.3)].

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness of cilostazol tablets in pediatric patients have not been established.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the total number of subjects (n = 2,274) in clinical studies of cilostazol tablets, 56 percent were 65 years old and over, while 16 percent were 75 years old and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be excluded.

Pharmacokinetic studies have not disclosed any age-related effects on the absorption, distribution, metabolism, and elimination of cilostazol and its metabolites.

Dosage forms

Philippines

  • Tablet: 50 mg, 100 mg
  • Extended-release tablet: 100 mg, 200 mg
  • Controlled-release tablet: 100 mg, 200 mg
  • Sustained-release capsule: 100 mg

Registered products in the Philippines

85 products registered with the Food and Drug Administration (FDA) Philippines list Cilostazol as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products85
Philippine FDA-registered products for Cilostazol
Package insert
AggravanCilostazol
50 mg TabletFoil Strip x 10's (Box of 30's)
Rx
PT DEXA MEDICAIndonesia
Glorious Dexa Mandaya, Inc
DRP-6007
Jan 20, 2029
CatazolCilostazol
100 mg TabletFoil Strip x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
—
DRP-8570
Apr 20, 2030
Ciloheme 100Cilostazol
100 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Cooper Pharma LimitedIndia
Ambica International Corporation.Importer: Ambica International Corporation
DRP-14373
Aug 30, 2028
Ciloheme 50Cilostazol
50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Cooper Pharma LimitedIndia
Ambica International Corporation.Importer: Ambica International Corporation
DRP-14374
Aug 30, 2028
CiloproCilostazol
100 mg TabletAlu/Alu Strip Foil x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Transcend Phils., Inc.
DRP-7523
Mar 11, 2030
Cilosol 100Cilostazol
100 mg TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 100's) xx 10's (Box of 100's)
Rx
Unison Laboratories Co., Ltd.Thailand
Justright Healthcare Inc.
DR-XY48784
Jun 23, 2028
Cilosol 50Cilostazol
50 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Unison Laboratories Co., Ltd.Thailand
JustRight Healthcare Inc.
DR-XY47385
Sep 15, 2031
CilostadinCilostazol
100 mg TabletBlister Pack x 10’s (Box of 100’s)
Rx
Cadila Pharmaceuticals LimitedIndia
Importer: Medchoice CNS Pharma Corporation
DRP-5650-05
Jul 9, 2027
CilostadinCilostazol
50 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s)
Rx
Cadila Pharmaceuticals LimitedIndia
Medchoice CNS Pharma CorporationImporter: Ambica International Corporation
DRP-4555-04
Dec 9, 2027
Cilostal-100Cilostazol
100 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation.Importer: Ambica International Corporation
DRP-14744
Dec 20, 2028
Cilostal-50Cilostazol
50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-19093
Oct 27, 2031
Cilostan CrCilostazol
100 mg Controlled Release TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Korea United Pharm. Inc.Korea
One Pharma Marketing Inc.
DR-XY48745
Jun 5, 2028
Cilostan CRCilostazol
200 mg Controlled-Release TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets)
Rx
Korea United Pharm. Inc.Republic of Korea
One Pharma Marketing Inc.
DR-XY44984
Jan 19, 2032
Cilozallen-B50Cilostazol
50 mg TabletAlu/Clear Pvc Blister Pack Of 10'S (Box of 100's)
Rx
Belco PharmaIndia
Ollen Pharma Trading Inc.
DRP-17966
Apr 30, 2031
CiloziaCilostazol
50 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Magbro Healthcare Pvt. Ltd.India
Teramedix Pharma Trading Inc.
DRP-16282
Jan 27, 2030
Cilozol-100Cilostazol
100 mg tabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Micro Labs LimitedIndia
Brown & Burk Philippines Inc.
DRP-8518
Oct 24, 2029
Cilozol-50Cilostazol
50 mg TabletAlu/Alu Blister Pack x 10's Box of 30's
Rx
Micro Labs LimitedIndia
Brown & Burk Philippines Inc.
DRP-8519
Oct 24, 2029
CirozitCilostazol
100 mg TabletAlu/PVC Blister Pack x 10's (Box of 10's)
Rx
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-14655
Nov 17, 2028
ClaudenCilostazol
100 mg TabletFoil Strip x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
Aldril Pharmaceuticals, Inc.Trader: Total Care Pharma Inc.
DRP-15052
Apr 16, 2030
ClaudenCilostazol
50 mg TabletAluminum Foil Strip x 10's Box of 30's
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Totalcare Pharma Inc.
DR-XY43330
Apr 1, 2029
ClaudenCilostazol
50 mg TabletAluminum Foil Strip x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: TotalCare Pharma Inc.
DRP-16126
Apr 1, 2029
Claudisaph-GE 100Cilostazol
100 mg TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s)
Rx
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-17967
Apr 16, 2031
ClazolCilostazol
100 mg TabletAluminum Foil Strip x 10s (Box of 50's)
Rx
Macleods Pharmaceuticals Limited (Unit II)India
Zuellig Pharma CorporationImporter: OEP Philippines, Inc.
DRP-7541
Nov 28, 2031
ClazolCilostazol
50 mg Tablet
Rx
Macleods Pharmaceuticals Limited (Unit II)
Zuellig Pharma CorporationImporter: OEP Philippines, Inc.
DRP-7191
Nov 27, 2026
CloscizolCilostazol
100 mg TabletBlister Pack x 10’s (Box of 100’s)
Rx
Cadila Pharmaceuticals LimitedIndia
Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation
DRP-5650-07
Jul 9, 2027
CloscizolCilostazol
50 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s)
Rx
Cadila Pharmaceuticals LimitedIndia
Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation
DRP-4555-07
Dec 9, 2027
Clostelo 100Cilostazol
100 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
Rx
Cooper Pharma LimitedIndia
Bewell Nutraceuticals Corp.Importer: Ambica International Corporation
DRP-14373-02
Aug 30, 2028
Clostelo 100Cilostazol
100 mg TabletBlister Pack x 10's (Box of 100's)
Rx
Cadila Pharmaceuticals LimitedIndia
Bewell Nutraceuticals Corp.Importer: Ambica International Corporation
DRP-5650-08
Jul 9, 2027
Clostelo 50Cilostazol
50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
Rx
Cooper Pharma LimitedIndia
Bewell Nutraceuticals Corp.Importer: Ambica International Corporation
DRP-14374-03
Aug 30, 2028
Clostelo 50Cilostazol
50 mg TabletAlu/PVC Blister Pack x 10’s Box of 100’s
Rx
Cadila Pharmaceuticals LimitedIndia
Bewell Nutraceuticals Corp.Importer: Ambica International Corporation
DRP-4555-08
Dec 9, 2027
ClotecCilostazol
50 mg TabletAlu/Alu Blister Pack x 10's (Box of 10 blister packs x 10 tablets)
Rx
Magbro Healthcare Pvt. Ltd.India
Pharmakon Biotec Inc.
DRP-14045
Jun 8, 2028
DisolvCilostazol
100 mg TabletAlu-Alu Blister pack x 10's (Box of 30's)
Rx
Cooper Pharma LImitedIndia
Preventia Healthcare Inc,Importer: Suhitas Pharmaceuticals Inc.
DRP-5350
Jun 20, 2027
DisolvCilostazol
50 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's)
Rx
Cooper Pharma LimitedIndia
Preventia Healthcare Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-5441
Aug 15, 2027
Gociflex 50Cilostazol
50 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Cooper Pharma LimitedIndia
Applied Pharmaceutical Distribution Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-5441-02
Aug 15, 2027
Hematozol 100Cilostazol
100 mg TabletBlister Pack x 10’s (Box of 100’s)
Rx
Cadila Pharmaceuticals LimitedIndia
Diafarm Inc.Importer: Ambica International Corporation
DRP-5650-06
Jul 9, 2027
Hematozol 50Cilostazol
50 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s)
Rx
Cadila Pharmaceuticals LimitedIndia
Diafarm Inc.Importer: Ambica International Corporation
DRP-4555-09
Dec 9, 2027
NoneCilostazol
100 mg Extended Release TabletAlu/Clear PVC Blister pack x 10's (Box of 100's)
Rx
Novagen Healthcare Private LimitedIndia
Medethix, Inc.
DRP-17527
Sep 9, 2031
NoneCilostazol
100 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Cooper Pharma LimitedIndia
Diafarm Inc.Importer: Ambica International Corporation
DRP-14373-01
Aug 30, 2028
NoneCilostazol
100 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100’s)
Rx
Cooper Pharma LimitedIndia
Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation
DRP-14373-03
Aug 30, 2028
NoneCilostazol
100 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Reta DrugImporter: Ambica International Corporation
DRP-14744-02
Dec 20, 2028
NoneCilostazol
100 mg TabletBlister Pack x 10’s (Box of 100’s)
Rx
Cadila Pharmaceuticals LimitedIndia
Actimed, Inc.Importer: Ambica International Corporation
DRP-5650-02
Jul 9, 2027
NoneCilostazol
100 mg TabletBlister Pack x 10's (Box of 100's)
Rx
Korea Otsuka Pharmaceutical Co., Ltd.Republic of Korea
Philusa CorporationImporter: Otsuka (Philippines) Pharmaceutical, Inc.
DRP-6289-01
May 22, 2029
NoneCilostazol
100 mg TabletFoil Strip x 10's Box of 30's
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Vitalink Health Products, Inc.
DRP-8726
Mar 11, 2030
NoneCilostazol
200 mg Extended Release TabletAlu/Clear PVC Blister pack x 10's (Box of 100's)
Rx
Novagen Healthcare Private LimitedIndia
Medethix, Inc.
DRP-17526
Sep 9, 2031
NoneCilostazol
50 mg TabletAlu/Foil Strip x 10's Box of 30's
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Dr. Zen’s Research, Inc.
DR-XY46165
Nov 21, 2027
NoneCilostazol
50 mg TabletAlu/Foil Strip x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Dr. Zen’s Research, Inc.
DRP-13708
Nov 21, 2027
NoneCilostazol
50 mg TabletAlu/Foil Strip x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
Actimed, Inc.Trader: Dr. Zen's Research, Inc.
DRP-13708-01
Nov 21, 2027
NoneCilostazol
50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Cooper Pharma LimitedIndia
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-14374-01
Aug 30, 2028
NoneCilostazol
50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Cooper Pharma LimitedIndia
Diafarm Inc.Importer: Ambica International Corporation
DRP-14374-02
Aug 30, 2028
NoneCilostazol
50 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Cooper Pharma LimitedIndia
Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation
DRP-14374-05
Aug 30, 2028
NoneCilostazol
50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s)
Rx
Cooper Pharma LimitedIndia
Reta DrugImporter: Ambica International Corporation
DRP-14374-06
Aug 30, 2028
NoneCilostazol
50 mg TabletAlu/PVC Blister Pack x 10’s Box of 100’s
Rx
Cadila Pharmaceuticals LimitedIndia
Actimed, Inc.Importer: Ambica International Corporation
DRP-4555-03
Dec 9, 2027
NoneCilostazol
50 mg TabletBlister Pack x 10's Box of 100's
Rx
Korea Otsuka Pharmaceutical Co., Ltd.Republic of Korea
Philusa CorporationImporter: Otsuka (Philippines) Pharmaceutical, Inc.
DRP-6290-01
May 22, 2029
Ostaz-50Cilostazol
50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
4Care Lifescience Pvt. Ltd.India
Aglobal Care, IncImporter: Aglobal Care, Inc.
DR-XY14952
Feb 21, 2029
Ostaz-50Cilostazol
50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
4Care Lifescience Pvt. Ltd.India
Aglobal Care, IncImporter: Aglobal Care, Inc.
DRP-14951
Feb 21, 2029
Pencil 100Cilostazol
100 mg TabletBlister Pack x 10's (Box of 100's)
Rx
Cadila Pharmaceuticals LimitedIndia
Kaufmann Pharma Inc.Importer: Ambica International Corporation
DRP-5650
Jul 9, 2032
Pencil 50Cilostazol
50 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Cadila Pharmaceuticals LimitedIndia
Kaufmann Pharma Inc.Importer: Ambica International Corporation
DRP-4555
Dec 9, 2027
PlatecilCilostazol
100 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Towa Pharmaceutical Co., Ltd.Japan
Trader: Crisdy-Na Drug Corporation
DR-XY39304
Apr 13, 2028
PlatecilCilostazol
50 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Towa Pharmaceutical Co., Ltd.Japan
Trader: Crisdy-Na Drug Corporation
DR-XY39305
Apr 13, 2028
PlazolCilostazol
50 mg TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s)
Rx
Standard Chem. & Pharm Co., Ltd. Standard Chem. & Pharm Co., Ltd.Taiwan
PHIL PHARMAWEALTH, INC.
DR-XY42648
Sep 18, 2028
PletaalCilostazol
100 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's); Blister Pack x 15's
Rx
Korea Otsuka Pharmaceutical Co., Ltd.Republic of Korea
Importer: OTSUKA (PHILIPPINES) PHARMACEUTICAL, INC.
DRP-6289
May 22, 2029
PletaalCilostazol
50 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's); Alu/PVC Blister Pack x 15's
Rx
Korea Otsuka Pharmaceutical Co. Ltd.Korea
Importer: OTSUKA (PHILIPPINES) PHARMACEUTICAL, INC.
DRP-6290
May 22, 2029
Pletaal SRCilostazol
100 mg Sustained Release CapsuleAlu/Alu Blister Foil x 10's (Box of 60's)
Rx
Korea Otsuka Pharmaceutical Co., Ltd.Korea
Otsuka (Philippines) Pharmaceutical, Inc.
DRP-12858
Apr 4, 2030
PletarCilostazol
100 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-14744-01
Dec 20, 2028
PletaxolCilostazol
100 mg TabletFoil Strip x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-7495
Apr 16, 2030
PletaxolCilostazol
50 mg TabletAlu/Strip Foil x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-7494
Dec 18, 2029
PletazCilostazol
50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
Rx
Cooper Pharma LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-14374-04
Aug 30, 2028
PlezolCilostazol
50 mg TabletAlu/Alu Foil Strip x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Westfield Pharmaceuticals, Inc.
DRP-7522
Jul 15, 2029
Tazol 100Cilostazol
100 mg TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 30's); Alu/Clear PVC/PVDC Blister Pack x 10's (Box of 100's); Alu/Clear PVC/PVDC Blister Pack x 10's (Box of 10's as Physician Sample)
Rx
Zydus Lifesciences LimitedIndia
Zydus Healthcare Philippines Inc.
DRP-7305
Feb 26, 2031
Tazollen-B100Cilostazol
100 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Belco PharmaIndia
Ollen Pharma Trading Inc.
DRP-17109
Sep 30, 2031
ThromboranCilostazol
100 mg TabletAlu-Alu Blister pack x 10's (Box of 30's)
Rx
Cooper Pharma LimitedIndia
Orange Biotec Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-5350-01
Jun 20, 2027
ThromboranCilostazol
50 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's)
Rx
Cooper Pharma LimitedIndia
Orange Biotec Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-5441-01
Aug 15, 2027
ThromzolCilostazol
100 mg TabletBlister Pack x 10's (Box of 100's)
Rx
Cadila Pharmaceuticals LimitedIndia
Bell-Kenz Pharma Inc.Importer: Ambica International Corporation
DRP-5650-04
Jul 9, 2032
ThromzolCilostazol
50 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s)
Rx
Cadila Pharmaceuticals LimitedIndia
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-4555-06
Dec 9, 2027
Thromzol 100Cilostazol
100 mg Extended Release TabletAlu/Clear PVC Blister pack x 10's (Box of 100's)
Rx
Novagen Healthcare Private LimitedIndia
Bell-Kenz Pharma Inc.Importer: I.E. Medica, Inc.
DRP-17528-01
Jan 23, 2031
TrombocilCilostazol
100 mg TabletAlu Foil Strip x 10's (Box of 100s)
Rx
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, INC.
DRP-9890
Dec 12, 2027
TrombocilCilostazol
50 mg TabletAlu Foil Strip x 10's (Box of 100's)
Rx
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, INC.
DRP-9889
Nov 5, 2027
UnbrandedCilostazol
50 mg TabletAlu/Foil Strip x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Vitalink Health Products, Inc.
DRP-10188
May 26, 2029
VaxolCilostazol
100 mg TabletBlister Pack x 10's (Box of 100's)
Rx
Cadila Pharmaceuticals LimitedIndia
The Cathay YSS Distributors Co., Inc.Importer: Ambica International Corporation
DRP-5650-03
Jul 9, 2032
VaxolCilostazol
50 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s)
Rx
Cadila Pharmaceuticals LimitedIndia
The Cathay YSS Distributors Co., Inc.Importer: Ambica International Corporation
DRP-4555-05
Dec 9, 2027
ZatsolCilostazol
100 mg TabletBlister Pack x 10’s (Box of 100’s)
Rx
Cadila Pharmaceuticals LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-5650-01
Jul 9, 2027
ZatsolCilostazol
50 mg TabletAlu/PVC Blister Pack x 10’s Box of 100’s
Rx
Cadila Pharmaceuticals LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-4555-02
Dec 9, 2027
ZoloscaCilostazol
200 mg Extended Release TabletAlu/Clear PVC Blister pack x 10's (Box of 100's)
Rx
Novagen Healthcare Private LimitedIndia
Medethix, Inc.
DRP-17525
Sep 9, 2031
(no brand name)Cilostazol
100 mg Extended Release TabletAlu/Clear PVC Blister pack x 10's (Box of 100's)
Rx
Novagen Healthcare Private LimitedIndia
I.E Medica, Inc.
DRP-17528
Jan 23, 2031
(no brand name)Cilostazol
50 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s)
Rx
Cadila Pharmaceuticals LimitedIndia
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-4555-01
Dec 9, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Cilostazol Tablets, USP are available containing 50 mg or 100 mg of cilostazol USP. The 50 mg tablets are white to off-white, round, flat bevel edged tablets debossed with ‘CI’ on one side and ‘50’ on other side. The 100 mg tablets are white to off-white, round, flat bevel edged tablets debossed with ‘CI’ on one side and ‘100’ on other side. Tablets: 50 mg and 100 mg (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • Risks of tachycardia, palpitation, tachyarrhythmia or hypotension. Risks of exacerbations of angina pectoris or myocardial infarction in patients with a history of ischemic heart disease (5.2)
  • Left ventricular outflow tract obstruction has been reported in patients with sigmoid shaped interventricular septum (5.1)
  • Risks of thrombocytopenia or leukopenia progressing to agranulocytosis- monitor platelets and white blood cell counts (5.3)
  • Avoid use in patients with hemostatic disorders or active pathologic bleeding (5.4)
5.1 Tachycardia

5.1 Tachycardia Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension. The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm. Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.

5.2 Left Ventricular Outflow Tract Obstruction

5.2 Left Ventricular Outflow Tract Obstruction Left ventricular outflow tract obstruction has been reported in patients with sigmoid shaped interventricular septum. Monitor patients for the development of a new systolic murmur or cardiac symptoms after starting cilostazol.

5.3 Hematologic Adverse Reactions

5.3 Hematologic Adverse Reactions Cases of thrombocytopenia or leukopenia progressing to agranulocytosis when cilostazol tablets were not immediately discontinued have been reported. Agranulocytosis is reversible on discontinuation of cilostazol tablets. Monitor platelets and white blood cell counts periodically.

5.4 Hemostatic Disorders or Active Pathologic Bleeding

5.4 Hemostatic Disorders or Active Pathologic Bleeding Cilostazol tablets inhibit platelet aggregation in a reversible manner. Cilostazol tablets have not been studied in patients with hemostatic disorders or active pathologic bleeding. Avoid use of cilostazol tablets in these patients.

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Strong and moderate CYP3A4 and CYP2C19 inhibitors: Increase exposure to cilostazol tablets. Reduce cilostazol tablets dose (2.2, 7.1) 7.1 Inhibitors of CYP3A4 or CYP2C19 Inhibitors of CYP3A4: Coadministration of strong (e.g., ketoconazole) and moderate (e.g., erythromycin, diltiazem and grapefruit juice) CYP3A4 inhibitors can increase exposure to cilostazol tablets.

Reduce cilostazol tablets dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP3A4 [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)]. Inhibitors of CYP2C19: Coadministration with CYP2C19 inhibitors (e.g., omeprazole) increases systemic exposure of cilostazol tablets active metabolites.

Reduce cilostazol tablets dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP2C19 [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)].

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Based on in vitro studies, the primary isoenzymes involved in cilostazol’s metabolism are CYP3A4 and, to a lesser extent, CYP2C19.

Drug Interactions: Cilostazol does not appear to inhibit CYP3A4 .

Strong Inhibitors of CYP3A4: A priming dose of ketoconazole 400 mg (a strong inhibitor of CYP3A4), was given one day prior to coadministration of single doses of ketoconazole 400 mg and cilostazol 100 mg.

Other strong inhibitors of CYP3A4, such as itraconazole, voriconazole, clarithromycin, ritonavir, saquinavir, and nefazodone would be expected to have a similar effect [see Dosage and Administration (2.2) , Drug Interactions (7.1) ] .

Moderate Inhibitors of CYP3A4: Erythromycin and Other Macrolide Antibiotics : Erythromycin is a moderately strong inhibitor of CYP3A4.

Inhibitors of CYP2C19: Omeprazole: Coadministration of omeprazole did not significantly affect the metabolism of cilostazol, but the systemic exposure to 3,4-dehydro-cilostazol was increased by 69%, probably the result of omeprazole’s potent inhibition of CYP2C19 [ see Dosage and Administration (2.2) ] .

7 DRUG INTERACTIONS Strong and moderate CYP3A4 and CYP2C19 inhibitors : Increase exposure to cilostazol tablets.

Reduce cilostazol tablets dose ( 2.2 , 7.1 ) 7.1 Inhibitors of CYP3A4 or CYP2C19 Inhibitors of CYP3A4: Coadministration of strong (e.g., ketoconazole) and moderate (e.g., erythromycin, diltiazem and grapefruit juice) CYP3A4 inhibitors can increase exposure to cilostazol tablets.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following adverse reactions are discussed in greater detail in other sections of the labeling: Patients with Heart Failure [see Boxed Warning] Tachycardia [see Warnings and Precautions (5.1)] Left Ventricular Outflow Tract Obstruction [see Warnings and Precautions (5.2)] Hematologic Adverse Reactions [see Warnings and Precautions (5.3)] Hemostatic Disorders or Active Pathologic Bleeding [see Warnings and Precautions 5.4)] Most common adverse reactions greater than or equal to 2% and at least twice that for placebo in patients on 100 mg twice daily are headache, diarrhea, abnormal stools, and palpitation (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions were assessed in eight placebo-controlled clinical trials involving patients exposed to either 50 or 100 mg twice daily cilostazol tablets (n = 1301) or placebo (n = 973), with a median treatment duration of 127 days for patients on cilostazol tablets and 134 days for patients on placebo.

The most frequent adverse reaction resulting in discontinuation of therapy in more than 3% of patients treated with cilostazol tablets was headache [50 mg twice daily (1.3%), 100 mg twice daily (3.5%) and placebo (0.3%)]. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol tablets (all doses) versus 0.1% for placebo.

The most common adverse reactions, occurring in at least 2% of patients treated with cilostazol tablets 50 or 100 mg twice daily, are shown in Table 1. Table 1: Most Common Adverse Reactions in Patients on Cilostazol Tablets 50 or 100 mg Twice Daily (Incidence at least 2% and Occurring More Frequently (≥ 2%) in the 100 mg Twice Daily Group than on Placebo) Adverse Reactions Placebo (N = 973) Cilostazol Tablets 50 mg twice daily (N = 303) Cilostazol Tablets 100 mg twice daily (N = 998) Headache 14% 27% 34% Diarrhea 7% 12% 19% Abnormal stools 4% 12% 15% Palpitation 1% 5% 10% Dizziness 6% 9% 10% Pharyngitis 7% 7% 10% Infection 8% 14% 10% Peripheral edema 4% 9% 7% Rhinitis 5% 12% 7% Dyspepsia 4% 6% 6% Abdominal pain 3% 4% 5% Tachycardia 1% 4% 4% Less frequent clinical significant adverse reactions (less than 2%) that were experienced by patients treated with cilostazol tablets 50 mg twice daily or 100 mg twice daily in the eight controlled clinical trials and that occurred at a frequency in the 100 mg twice daily group greater than in the placebo group are listed below.

Body as a Whole: fever, generalized edema, malaise Cardiovascular: atrial fibrillation, heart failure, myocardial infarction, nodal arrhythmia, supraventricular tachycardia, ventricular extrasystoles, ventricular tachycardia Digestive: anorexia, melena Hematologic and Lymphatic: anemia Metabolic and Nutritional: increased creatinine, hyperuricemia Nervous: insomnia Respiratory: epistaxis Skin and Appendages: urticaria Special Senses: conjunctivitis, retinal hemorrhage, tinnitus Urogenital: urinary frequency

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of cilostazol tablets. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and Lymphatic System Disorders: Aplastic anemia, granulocytopenia, pancytopenia, bleeding tendency Cardiac Disorders: Torsade de pointes and QTc prolongation in patients with cardiac disorders (e.g., complete atrioventricular block, heart failure; and bradyarrythmia), angina pectoris. Gastrointestinal Disorders: Gastrointestinal hemorrhage, vomiting, flatulence, nausea General Disorders and Administration Site Conditions: Pain, chest pain, hot flushes Hepatobiliary Disorders: Hepatic dysfunction/abnormal liver function tests, jaundice Immune System Disorders: Anaphylaxis, angioedema, and hypersensitivity Investigations: Blood glucose increased, blood uric acid increased, increase in BUN (blood urea increased), blood pressure increase Nervous System Disorders: Intracranial hemorrhage, cerebral hemorrhage, cerebrovascular accident, extradural hematoma and subdural hematoma Renal and Urinary Disorders: Hematuria Respiratory, Thoracic and Mediastinal Disorders: Pulmonary hemorrhage, interstitial pneumonia Skin and Subcutaneous Tissue Disorders: Hemorrhage subcutaneous, pruritus, skin eruptions including Stevens-Johnson syndrome, skin drug eruption (dermatitis medicamentosa), rash Vascular Disorders: Subacute stent thrombosis, hypertension.

Adverse reaction frequency tables (US label) US FDA label
Table 1: Most Common Adverse Reactions in Patients on Cilostazol Tablets 50 or 100 mg Twice Daily (Incidence at least 2% and Occurring More Frequently (≥ 2%) in the 100 mg Twice Daily Group than on Placebo)
Adverse Reactions Placebo (N = 973) Cilostazol Tablets 50 mg twice daily (N = 303) Cilostazol Tablets 100 mg twice daily (N = 998)
Headache 14% 27% 34%
Diarrhea 7% 12% 19%
Abnormal stools 4% 12% 15%
Palpitation 1% 5% 10%
Dizziness 6% 9% 10%
Pharyngitis 7% 7% 10%
Infection 8% 14% 10%
Peripheral edema 4% 9% 7%
Rhinitis 5% 12% 7%
Dyspepsia 4% 6% 6%
Abdominal pain 3% 4% 5%
Tachycardia 1% 4% 4%

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Teratogenic Effects: Pregnancy Category C: Cilostazol tablets have been shown to be teratogenic in rats at doses that are greater than 5-times the human MRHD on a body surface area basis. There are no adequate and well-controlled studies in pregnant women. In a rat developmental toxicity study, oral administration of 1000 mg cilostazol/kg/day was associated with decreased fetal weights, and increased incidences of cardiovascular, renal, and skeletal anomalies (ventricular septal, aortic arch and subclavian artery abnormalities, renal pelvic dilation, 14th rib, and retarded ossification).

At this dose, systemic exposure to unbound cilostazol in nonpregnant rats was about 5 times the exposure in humans given the MRHD. Increased incidences of ventricular septal defect and retarded ossification were also noted at 150 mg/kg/day (5 times the MRHD on a systemic exposure basis). In a rabbit developmental toxicity study, an increased incidence of retardation of ossification of the sternum was seen at doses as low as 150 mg/kg/day.

In nonpregnant rabbits given 150 mg/kg/day, exposure to unbound cilostazol was considerably lower than that seen in humans given the MRHD, and exposure to 3,4-dehydro-cilostazol was barely detectable. When cilostazol was administered to rats during late pregnancy and lactation, an increased incidence of stillborn and decreased birth weights of offspring was seen at doses of 150 mg/kg/day (5 times the MRHD on a systemic exposure basis).

Breastfeeding considerations

Lactation (US label) US FDA label

8.3 Nursing Mothers Transfer of cilostazol into milk has been reported in rats. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from cilostazol tablets, discontinue nursing or discontinue cilostazol tablets.

Mechanism of action

12.1 Mechanism of Action Cilostazol tablets and several of its metabolites inhibit phosphodiesterase III activity and suppress cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation, respectively. Cilostazol tablets reversibly inhibit platelet aggregation induced by a variety of stimuli, including thrombin, ADP, collagen, arachidonic acid, epinephrine, and shear stress.

Cardiovascular Effects: Cilostazol affects both vascular beds and cardiovascular function. It produces heterogeneous dilation of vascular beds, with greater dilation in femoral beds than in vertebral, carotid or superior mesenteric arteries. Renal arteries were not responsive to the effects of cilostazol. In dogs or cynomolgus monkeys, cilostazol increased heart rate, myocardial contractile force, and coronary blood flow as well as ventricular automaticity, as would be expected for a PDE III inhibitor.

Left ventricular contractility was increased at doses required to inhibit platelet aggregation. A-V conduction was accelerated. In humans, heart rate increased in a dose-proportional manner by a mean of 5.1 and 7.4 beats per minute in patients treated with 50 and 100 mg twice daily, respectively.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Cilostazol's effects on platelet aggregation were evaluated in both healthy subjects and in patients with stable symptoms of cerebral thrombosis, cerebral embolism, transient ischemic attack, or cerebral arteriosclerosis over a range of doses from 50 mg every day to 100 mg three times a day. Cilostazol significantly inhibited platelet aggregation in a dose-dependent manner.

The effects were observed as early as 3 hours post-dose and lasted up to 12 hours following a single dose. Following chronic administration and withdrawal of cilostazol, the effects on platelet aggregation began to subside 48 hours after withdrawal and returned to baseline by 96 hours with no rebound effect. A cilostazol dosage of 100 mg twice daily consistently inhibited platelet aggregation induced with arachidonic acid, collagen and adenosine diphosphate (ADP).

Bleeding time was not affected by cilostazol administration. Effects on circulating plasma lipids have been examined in patients taking cilostazol tablets. After 12 weeks, as compared to placebo, cilostazol tablets 100 mg twice daily produced a reduction in triglycerides of 29.3 mg/dL (15%) and an increase in HDL-cholesterol of 4.0 mg/dL (≅ 10%).

Drug Interactions: Aspirin: Short-term (less than or equal to 4 days) coadministration of aspirin with cilostazol tablets increased the inhibition of ADP-induced ex vivo platelet aggregation by 22% to 37% when compared to either aspirin or cilostazol tablets alone. Short-term (less than or equal to 4 days) coadministration of aspirin with cilostazol tablets increased the inhibition of arachidonic acid-induced ex vivo platelet aggregation by 20% compared to cilostazol tablets alone and by 48% compared to aspirin alone.

However, short-term coadministration of aspirin with cilostazol tablets had no clinically significant impact on PT, aPTT, or bleeding time compared to aspirin alone. Effects of long-term coadministration in the general population are unknown. In eight randomized, placebo-controlled, double-blind clinical trials, aspirin was coadministered with cilostazol to 201 patients.

The most frequent doses and mean durations of aspirin therapy were 75 to 81 mg daily for 137 days (107 patients) and 325 mg daily for 54 days (85 patients). There was no apparent increase in frequency of hemorrhagic adverse effects in patients taking cilostazol and aspirin compared to patients taking placebo and equivalent doses of aspirin.

Warfarin: Cilostazol did not inhibit the pharmacologic effects (PT, aPTT, bleeding time, or platelet aggregation) of R- and S-warfarin after a single 25 mg dose of warfarin. The effect of concomitant multiple dosing of warfarin and cilostazol tablets on the pharmacodynamics of both drugs is unknown.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Cilostazol is extensively metabolized by hepatic cytochrome P-450 enzymes, mainly 3A4, and, to a lesser extent, 2C19, with metabolites largely excreted in urine.

Metabolism: Cilostazol is eliminated predominantly by metabolism and subsequent urinary excretion of metabolites.

Elimination: The primary route of elimination was via the urine (74%), with the remainder excreted in feces (20%).

No measurable amount of unchanged cilostazol was excreted in the urine, and less than 2% of the dose was excreted as 3,4-dehydrocilostazol.

About 30% of the dose was excreted in urine as 4´-trans-hydroxy-cilostazol.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Cilostazol tablets are absorbed after oral administration. A high fat meal increases absorption, with an approximately 90% increase in C max and a 25% increase in AUC. Absolute bioavailability is not known. Cilostazol is extensively metabolized by hepatic cytochrome P-450 enzymes, mainly 3A4, and, to a lesser extent, 2C19, with metabolites largely excreted in urine.

Two metabolites are active, with one metabolite appearing to account for at least 50% of the pharmacologic (PDE III inhibition) activity after administration of cilostazol tablets. Pharmacokinetics are approximately dose proportional. Cilostazol and its active metabolites have apparent elimination half-lives of about 11-13 hours.

Cilostazol and its active metabolites accumulate about 2-fold with chronic administration and reach steady state blood levels within a few days. The pharmacokinetics of cilostazol and its two major active metabolites were similar in healthy subjects and patients with intermittent claudication due to peripheral arterial disease (PAD).

Figure 1 shows the mean plasma concentration-time profile at steady state after multiple dosing of cilostazol tablets 100 mg twice daily. Figure 1: Mean Plasma Concentration-time Profile at Steady State after Multiple Dosing of Cilostazol Tablets 100 mg Twice Daily Distribution: Cilostazol is 95 to 98% protein bound, predominantly to albumin.

The binding for 3,4-dehydro-cilostazol is 97.4% and for 4´-trans-hydroxy-cilostazol is 66%. Mild hepatic impairment did not affect protein binding. The free fraction of cilostazol was 27% higher in subjects with renal impairment than in healthy volunteers. The displacement of cilostazol from plasma proteins by erythromycin, quinidine, warfarin, and omeprazole was not clinically significant.

Metabolism: Cilostazol is eliminated predominantly by metabolism and subsequent urinary excretion of metabolites. Based on in vitro studies, the primary isoenzymes involved in cilostazol’s metabolism are CYP3A4 and, to a lesser extent, CYP2C19. The enzyme responsible for metabolism of 3,4-dehydro-cilostazol, the most active of the metabolites, is unknown.

Following oral administration of 100 mg radiolabeled cilostazol, 56% of the total analytes in plasma was cilostazol, 15% was 3,4-dehydro-cilostazol (4 to 7 times as active as cilostazol), and 4% was 4´-trans-hydroxy-cilostazol (20% as active as cilostazol). Elimination: The primary route of elimination was via the urine (74%), with the remainder excreted in feces (20%).

No measurable amount of unchanged cilostazol was excreted in the urine, and less than 2% of the dose was excreted as 3,4-dehydrocilostazol. About 30% of the dose was excreted in urine as 4´-trans-hydroxy-cilostazol. The remainder was excreted as other metabolites, none of which exceeded 5%. There was no evidence of induction of hepatic microenzymes.

Special Populations: Age and Gender: The total and unbound oral clearances, adjusted for body weight, of cilostazol and its metabolites were not significantly different with respect to age (50 to 80 years) or gender. Smokers: Population pharmacokinetic analysis suggests that smoking decreased cilostazol exposure by about 20%.

Hepatic Impairment: The pharmacokinetics of cilostazol and its metabolites were similar in subjects with mild hepatic disease as compared to healthy subjects. Patients with moderate or severe hepatic impairment have not been studied. Renal Impairment: The total pharmacologic activity of cilostazol and its metabolites was similar in subjects with mild to moderate renal impairment and in healthy subjects.

Severe renal impairment increases metabolite levels and alters protein binding of the parent. The expected pharmacologic activity, however, based on plasma concentrations and relative PDE III inhibiting potency of parent drug and metabolites, appeared little changed. Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95 to 98%).

Drug Interactions: Cilostazol does not appear to inhibit CYP3A4. Warfarin: Cilostazol did not inhibit the metabolism of R- and S-warfarin after a single 25 mg dose of warfarin. Clopidogrel: Multiple doses of clopidogrel do not significantly increase steady state plasma concentrations of cilostazol. Strong Inhibitors of CYP3A4: A priming dose of ketoconazole 400 mg (a strong inhibitor of CYP3A4), was given one day prior to coadministration of single doses of ketoconazole 400 mg and cilostazol 100 mg.

This regimen increased cilostazol C max by 94% and AUC by 117%. Other strong inhibitors of CYP3A4, such as itraconazole, voriconazole, clarithromycin, ritonavir, saquinavir, and nefazodone would be expected to have a similar effect [see Dosage and Administration (2.2), Drug Interactions (7.1)]. Moderate Inhibitors of CYP3A4: Erythromycin and Other Macrolide Antibiotics: Erythromycin is a moderately strong inhibitor of CYP3A4.

Coadministration of erythromycin 500 mg every 8h with a single dose of cilostazol 100 mg increased cilostazol C max by 47% and AUC by 73%. Inhibition of cilostazol metabolism by erythromycin increased the AUC of 4´-trans-hydroxycilostazol by 141% [see Dosage and Administration (2.2)]. Diltiazem: Diltiazem 180 mg decreased the clearance of cilostazol by ~30%.

Cilostazol C max increased ~30% and AUC increased ~40% [see Dosage and Administration (2.2)]. Grapefruit Juice: Grapefruit juice increased the C max of cilostazol by ~50%, but had no effect on AUC. Inhibitors of CYP2C19: Omeprazole: Coadministration of omeprazole did not significantly affect the metabolism of cilostazol, but the systemic exposure to 3,4-dehydro-cilostazol was increased by 69%, probably the result of omeprazole’s potent inhibition of CYP2C19 [see Dosage and Administration (2.2)].

Quinidine: Concomitant administration of quinidine with a single dose of cilostazol 100 mg did not alter cilostazol pharmacokinetics. Lovastatin: The concomitant administration of lovastatin with cilostazol decreases cilostazol C ss, max and AUC τ by 15%. There is also a decrease, although nonsignificant, in cilostazol metabolite concentrations.

Coadministration of cilostazol with lovastatin increases lovastatin and ß-hydroxylovastatin AUC approximately 70% and is not expected to be clinically significant. Figure 1

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Cilostazol 50 mg Tablet₱6.50–₱11.55Reference ₱7.72per tabletDPRI procurement range
Cilostazol 100 mg Tablet₱12.50–₱16.00Reference ₱12.85per tabletDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Cilostazol
PNF listingOral: 50 mg and 100 mg tablet
PNF listingOral: 50 mg (20% w/w), 0.25 g sachet powder for oral
PNF listingOral: use
PNF listingOral: 100 mg (20% w/w), 0.5 g sachet powder for oral use
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. CILOSTAZOL · Aurobindo Pharma Limited [US FDA-approved label, version 1, October 1, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c841eed-a98f-43c3-baaf-bf5502207a69
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .